

**Table 11-2. Summary of CNS/LM Progression-Free Survival of Subjects in the Full Analysis Set**

		<50 mCi (N=8)	50 mCi (N=94)	>50 mCi (N=5)	All Subjects (N=107)
Patient Status [n (%)]	Failed	3 (37.5)	53 (56.4)	2 (40.0)	58 (54.2)
	Censored	5 (62.5)	41 (43.6)	3 (60.0)	49 (45.8)
Cause of Failure [n (%)]	CNS Progression	1 (33.3)	28 (52.8)	1 (50.0)	30 (51.7)
	Death	2 (66.7)	25 (47.2)	1 (50.0)	28 (48.3)
12 Month CNS/LM PFS Proportion	KM Estimate	1	0.55	0.60	0.59
	95% CI	(1.00, 1.00)	(0.44, 0.65)	(0.13, 0.88)	(0.48, 0.68)
PFS Percentiles (months)	75th Percentile (95% CI)	NE (46.2, NE)	NE (52.3, NE)	NE (0.7, NE)	NE (NE, NE)
	Median (95% CI)	NE (14.1, NE)	18.2 (9.9, 45.3)	NE (0.7, NE)	21.8 (11.3, 46.2)
	25th Percentile (95% CI)	32.0 (14.1, NE)	5.3 (3.9, 7.2)	2.5 (0.7, NE)	5.3 (4.0, 9.1)
	At Risk	8	94	5	107
	Censored	5	41	3	49

Source: [Table 14.2.1.2](#).

Note: For subjects under 3 years of age, dose groups were assigned based on the treatment dose before age adjustment (i.e. 33% or 50% dose reduction).

Note: Table 14.2.1.2 includes data collected after the data cut-off of 30 June 2019.

CI = confidence interval; CNS/LM = central nervous system/leptomeningeal.